SUO 2017: MRI Fusion Biopsy is Associated with a Higher Rate of Pathologic Downgrading at Radical Prostatectomy
Washington, DC (UroToday.com) MRI targeted fusion biopsy has higher sensitivity and specificity in predicting Gleason score compared with standard 12-core biopsy . Dr. Beksac and co-authors presented results of their study assessing MRI fusion biopsy and pathologic staging at the time of radical prostatectomy. Gleason score discordance may still occur post radical prostatectomy, which can impact decision-making. The objective of this study was to analyze the patterns of Gleason downgrading after standard biopsy versus fusion biopsy.
SUO 2017: Outcomes of Serial MRI/Ultrasound Fusion Targeted Biopsy
Washington, DC (UroToday.com) Dr. Hsiang and colleagues presented their results of men undergoing serial magnetic resonance imaging (MRI)/ultrasound fusion targeted biopsies in men with very low-risk and low-risk prostate cancer managed with active surveillance (AS). The outcomes and utility of serial MRI/ultrasound fusion targeted prostate biopsy in men with prostate cancer on AS have not been clearly defined. The objective of this study was to assess the rate of Gleason upgrading both on sequential fusion targeted and systematic biopsies among these specific men with prostate cancer.
SUO 2017: The Role of Inguinal Lymph Node Dissection in Men with Urethral Squamous Cell Carcinoma
Washington, DC (UroToday.com) Urethral squamous cell carcinoma (SCC) is a rare disease with limited clinical recommendations. Dr. Werntz and colleagues presented their population-level analysis assessing the impact of inguinal lymph node dissection in men with urethral SCC. Despite the similarities to penile cancer in terms of histology and lymphatic drainage, no consensus exists on the role of inguinal lymph node dissection for men with high-risk tumors. The objective of this study was to define the rate of inguinal lymph node dissection performance and its impact on survival.
SUO 2017: The REASSURE ME Trial
Washington, DC (UroToday.com) While active surveillance (AS) for the management of low risk prostate cancer is becoming an increasingly adopted treatment paradigm, many men and their partners can face a host of psychosocial stressors related to this approach. As such, Dr. Herrel and colleagues presented their trial design for the REASSURE ME trial, supporting emotion regulation, positive health behaviors, and surveillance adherence for men with prostate cancer on active surveillance. Psychosocial stressors can negatively affect short and long term psychosocial adjustment and quality of life and contribute to withdrawal from AS prematurely to seek definitive therapies such as surgery. The objective of this trial is to use a multi-site approach to examine the efficacy of mindfulness training compared with a time/attention−matched health promotion control among a large sample of men on AS and their spouses.
SUO 2017: Surgical And Imaging Findings Of Neoadjuvant Enzalutamide And Androgen Deprivation Therapy For High Risk Prostate Cancer: An Initial Case Study For An Ongoing Clinical Trial
Washington, DC (UroToday.com) Introduction: Neoadjuvant androgen deprivation therapy (ADT) for high-risk prostate cancer (PCa) has been shown to decrease the risk of positive surgical margins, but promotes no improvements in biochemical recurrence (BCR) or survival.
SUO 2017: Longitudinal Assessment Of Health-related Quality Of Life And Decisional Regret In Men With Localized Prostate Cancer
Washington, DC (UroToday.com) Introduction: Patients with clinically localized prostate cancer (PCa) are faced with the challenging process of selecting an optimal therapy for their disease. Treatment choice can impact health-related quality of life (HRQOL) specifically urinary, sexual, and bowel functioning that can further lead to the decisional regret.
SUO 2017: Primary Focal Cryoablation For Low-, Intermediate- And High-risk Prostate Cancer
Washington, DC (UroToday.com) Introduction: In this study the authors aimed to evaluate the oncologic and functional outcomes of primary focal cryoablation (PFC) for low-, intermediate- and high-risk prostate cancer (PCa) patients.